Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Vyome Holdings, Inc. (HIND)
Company Research
Source: Business Wire
Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debtDelivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectationsIndependent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal studyDisciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readoutsAdded a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big Pharma backgrounds, deep drug-development expertise, and experience across multiple FDA-approved therapies CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc., (“Vyome”) (Nasdaq: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its financial res
Show less
Read more
Impact Snapshot
Event Time:
HIND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIND alerts
High impacting Vyome Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
HIND
News
- Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 [Yahoo! Finance]Yahoo! Finance
- Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026Business Wire
- Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]Yahoo! Finance
- Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics CompanyBusiness Wire
- Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market OpportunityBusiness Wire
HIND
Sec Filings
- 3/31/26 - Form DEF
- 3/20/26 - Form PRE
- 3/18/26 - Form 10-K
- HIND's page on the SEC website